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Abstract
Methionine adenosyltransferases (MATs) are essential enzymes for life as they
produce S-adenosylmethionine (SAMe), the biological methyl donor required for
a plethora of reactions within the cell. Mammalian systems express two genes,
MAT1A and MAT2A, which encode for MATα1 and MATα2, the catalytic
subunits of the MAT isoenzymes, respectively. A third gene MAT2B, encodes a
regulatory subunit known as MATβ which controls the activity of MATα2.
MAT1A, which is mainly expressed in hepatocytes, maintains the differentiated
state of these cells, whilst MAT2A and MAT2B are expressed in extrahepatic
tissues as well as non-parenchymal cells of the liver (e.g., hepatic stellate and
Kupffer cells). The biosynthesis of SAMe is impaired in patients with chronic
liver disease and liver cancer due to decreased expression and inactivation of
MATα1. A switch from MAT1A to MAT2A/MAT2B occurs in multiple liver
diseases and during liver growth and dedifferentiation, but this change in the
expression pattern of MATs results in reduced hepatic SAMe level. Decades of
study have utilized the Mat1a-knockout (KO) mouse that spontaneously develops
non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC) to
elucidate a variety of mechanisms by which MAT proteins dysregulation
contributes to liver carcinogenesis. An increasing volume of work indicates that
MATs have SAMe-independent functions, distinct interactomes and multiple
subcellular localizations. Here we aim to provide an overview of MAT biology
including genes, isoenzymes and their regulation to provide the context for
understanding consequences of their dysregulation. We will highlight recent
breakthroughs in the field and underscore the importance of MAT’s in liver
tumorigenesis as well as their potential as targets for cancer therapy.
Key words: Methionine adenosyltransferases; S-adenosylmethionine; Liver cancer;
Hepatocellular carcinoma; Cholangiocarcinoma; Biomarkers; Therapeutic targets
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INTRODUCTION
This review examines the roles of methionine adenosyltransferases (MATs) in liver
cancers with a focus on how dysregulation of  these proteins contributes to their
pathogenesis. Hepatocellular carcinoma (HCC) is the most common primary liver
cancer and currently the second leading cause of cancer-related death worldwide[1]. In
the majority of the cases, HCC develops in patients with underlying chronic liver
disease and cirrhosis, which are mainly derived from viral hepatitis infection, alcohol
abuse and non-alcoholic fatty liver disease (NAFLD)[2]. The threat of HCC is expected
to continue rising due to increasing cases of  NAFLD given the obesity epidemic
occurring worldwide[3]. Even more alarming are reports of HCC from NAFLD that
occurred in the absence of cirrhosis[4]. Cholangiocarcinoma (CCA) is the second most
common primary liver cancer, which typically occur in the setting of chronic biliary
inflammation. MATs exert very similar roles in both types of liver cancers.
OVERVIEW OF MAT ENZYMES
MAT genes and isoenzymes
MATs (EC 2.5.1.6) belong to a family of enzymes that are essential to life as they
catalyze the biosynthesis of SAMe, the main methyl donor of the cell. Apart from
methylation,  SAMe  is  also  important  as  a  precursor  in  glutathione  (GSH)  and
polyamine  synthesis[5].  As  SAMe  is  used  for  the  methylation  of  biomolecules
including DNA, RNA, proteins, biological amines and phospholipids, any change in
its  biosynthesis  and catabolism within the cell  has  a  profound effect  on cellular
processes such as growth, differentiation and response to injury. Over the past decade
SAMe-independent roles of MAT enzymes have emerged, most notably, their ability
to function as bona fide transcription factors as well as their ability to form parts of
scaffold complexes which have been implicated in cancer development[6-9].
In mammals, three distinct genes, MAT1A, MAT2A, and MAT2B give rise to the
protein products MATα1, MATα2, and MATβ, respectively (Table 1,  Figure 1)[10].
MAT1A encodes for a 395-amino acid (396 in mouse, and 397 in rat) catalytic subunit
in humans that is mainly expressed in hepatocytes (parenchymal cells of the liver) as
well  as  bile  duct  epithelial  cells  and  pancreatic  acinar  cells[8,11].  MATα1  can
oligomerize to form a homotetramer (MATIII) or homodimer (MATI). The MATα2
subunit, the extrahepatic catalytic protein (395 amino acids), that has an 84% sequence
identity to MATα1, can also form dimers and tetramers but with a bias towards the
dimer conformation[10,12,13]. MATα2 is expressed in non-parenchymal cells of the liver
as well as in all extrahepatic tissues. The regulatory subunit MATβ has four known
isoforms, MATβV1, MATβV2, MATβV2a, and MATβV2b with the former two being
the major splice variants[14]. MATβV2a and MATβV2b are expressed at very low levels
compared to MATβV2 and have not been studied in detail[14]. MATβV1 is expressed in
fetal liver, prostate, lung, brain, thyroid and the adrenal gland, whilst MATβV2 is
expressed in skeletal muscle and heart. Both isoforms are expressed in the kidney and
thymus[14]. MATβV1 and MATβV2 are 331 and 323 amino acids long, respectively,
differ only by 20 amino acids at their N-terminus and share little sequence identity
(7%) to the catalytic  MAT proteins.  MATβ has a  binding pocket  for  the cofactor
NADP+, which can interact with both major isoforms[12,15].
MAT expression patterns and subcellular localization
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Table 1  Mammalian MAT genes and isoenzymes
Gene Protein Aminoacids
Alternative
names
Oligomeric
state
Regulatory
subunit Co-factors
Km for
methionine Km for ATP
Ki for
SAMe
X-ray
structure
MAT1A MATα1 395 MATIII
MAT(α1)2
Dimer No 210 μmol/L-
7 mmol
1-3 mmol None 20BV
MATI
MAT(α1)4
Tetramer No 23 μmol/L-1
mmol
0.2-0.5 mmol 400 μmol/L
MAT2A MATα2 395 MAT(α2)2 Dimer 4-10 μmol/L 70 μmol/L 60 μmol/L 5A19
MAT(α2)4 Tetramer 5A1I
MAT2B MATβV1 334 Monomeric NADP+
MATβV2 323 Monomeric NADP+ 2YDX
Historically, MATII in the literature refers to complexes of MATα2 and MATβ.
MAT enzymes were first thought to function as SAMe producing factories in the
cytosol, and that SAMe would be delivered to the specific compartments such as the
nucleus or mitochondria for methylation reactions[16]. However, a decade ago MATα1
was reported to be present within the nucleus[17]. This was followed by publications
describing MATα2, MATβV1 and MATβV2 to also be within this organelle[6,18]. These
publications showed that a nuclear location of MAT proteins was associated with
enhanced histone H3K27 methylation, an epigenetic modification that leads to gene
silencing[17]. Most recently MATα1 was reported to be present in the mitochondrial
matrix of hepatocytes, enhancing mitochondrial function and negatively regulating
cytochrome  P450  2E1  (CYP2E1)  through  methylation[19].  These  accumulating
publications  reinforce  the  concept  that  MATs  are  recruited  to  subcellular
compartments to provide a local source of SAMe.
Structural overview of MATs and MAT complexes
To date there are numerous crystal structures of MAT proteins from different species
in different active site conformations, complexed with substrates, products, or their
analogues[12,20-23].  The catalytic  proteins  have a  three-domain organization that  is
conserved amongst other MAT family subunits[21,22,24]. Monomeric MAT enzymes are
incapable of producing SAMe as they do not contain a complete active site. Upon
dimerization, both monomers contribute residues to form two active sites. The large
hydrophobic  surface  of  monomeric  MAT  constitutes  the  site  of  the  monomer-
monomer interface. A common feature of MAT enzymes is that they contain a “gating
loop” (in human MATα1 and α2 residues 113-131) that flanks the active site, which
has been hypothesized to move dynamically to allow access to the active site[21]. When
the active site is occupied, the loop closes to form a gate over the active site, but when
the active site is empty, the loop becomes disordered or open. MATα1 dimers can also
form tetramers through the central domain of the subunits[24]. Recent work has shown
that mutation to residues of the gating loop can reduce enzyme activity and SAMe
formation[25].
The regulatory βsubunit is structurally very different from the αsubunits, unable to
produce SAMe by itself. MATβ proteins contain signature motifs of the SDR (short-
chain dehydrogenase/reductase) superfamily including a Rossman fold that can bind
FAD+ or NADP+ although MATβ favors the latter[22]. MATα2 and MATβ interact to
give rise to the MATα2β complexes (also referred to as MATII)[12,26] (Figure 1, Table 1).
To date only the structure of a MATα2βV2 complex has been solved and it consists of
a MATα2 tetramer flanked by two MATβV2 subunits (MATα2(4)βV2(2)). This showed
that MATα2 can exist and function as a tetramer in the presence of MATβ[12].  The
oligomeric  state  of  this  crystal  structure,  confirmed  with  small  angle  x-ray
scattering[12], is different from the suggested tetrameric form [MAT(α2)2(β)2][27] or the
proposed  computational  model  in  which  MATαβ  was  assumed  to  be  a  trimer
[MAT(α2)2(β)1][15].  Mutational analysis showed by gel filtration that the minimum
motif required for the formation of the MAT(α2)4(βV2)2  complex comprises three
residues at the end of the C-terminus of MATβV2 (V321F322H323)[12]. Several publications,
using recombinant purified proteins, have shown that MATα1 can also interact with
MATβV1, although this interaction is several orders of magnitude weaker than that of
MATα2 and MATβ[12,25]. The MATα1βV1 complex is not likely to occur within the cell
as MATα1 and MATβ are generally not expressed at the same time.
MAT enzymatic mechanism
The  wealth  of  structures  available  for  MAT  enzymes,  as  well  as  the  range  of
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Figure 1
Figure 1  Schematic representation of the oligomeric states of mammalian MAT enzymes.MAT1A and MAT2A
genes encode the catalytic subunits MATα1 and MATα2, respectively. Both MATα1 and MATα2 can be organized as
dimers and tetramers. MAT2B encodes the regulatory subunit for which there are four isoforms, MATβV1, MATβV2,
MATβV2a, and MATβV2b with the former two being the major splice variants. MATα2 and MATβ interact to give rise
to the MATα2β complexes. The MAT(α2)4(βV1)2 and MAT(α2)4(βV2)2 complexes consist of a MATα2 tetramer
flanked by two MATβV1 or MATβV2 subunits.
biochemical evidence, has provided terrific detail  and insight into the enzymatic
mechanism. SAMe is produced by the addition of the amino acid methionine to the
energy molecule ATP (Figure 2). Upon entry of the substrates ATP and methionine
into the active site, the flexible gating loop becomes well-ordered closing the active
site. The synthesis of SAMe follows an SN2  catalytic mechanism[28,29],  whereby the
sulphur  atom  of  methionine  attacks  the  C5’  atom  of  ATP  displacing  the
tripolyphosphate (PPPi) moiety to form SAMe. The PPPi is then hydrolyzed giving
rise to pyrophosphate (PPi) and orthophosphate (Pi), providing the energy to facilitate
product  release  by dislodging the  gating loop[30].  For  a  detailed mechanism,  see
Komoto et al[21] 2004 and Murray et al[23] 2016.
MAT activity
Despite high sequence identity MAT enzymes exhibit different kinetic and regulatory
properties for methionine, ATP, and SAMe. The Km for the methionine is lowest in
MATα2 followed by MAT(α1)2 and is the highest for MAT(α1)4[5]. The Km for ATP is
also highest for MAT(α1)4 (1–2 mmol), intermediate for MAT(α1)2 (0.2–0.5 mmol), and
lowest for MATα2 (70 μM)[31,32]. SAMe, the product produced by MAT, can act as a
feedback inhibitor to some of these enzymes[33]. MATα2 is the most sensitive to SAMe
with a 50% inhibitory concentration (IC50)  of 60 μM which equates to the normal
physiological  liver  levels.  MAT(α1)4  is  minimally inhibited by SAMe (IC50  =  400
μmol/L) whilst MAT(α1)2  can be stimulated eight-fold by high SAMe levels (500
μmol/L)[33]. These differences between MATα1 and MATα2 are important to allow
MATα1 to  maintain  a  high  SAMe production  in  the  liver  (produces  6-8  g/day)
compared with MATα2, which does not contribute significantly to this SAMe pool[34].
Indeed, by expressing MATα1 the liver is able to catabolize 50% of methionine intake
via conversion to SAMe and allow an up to 10-fold rise in SAMe level following a
methionine rich meal[35]. Consistent with this, cells that express MATα1 have much
higher steady-state SAMe levels than cells that express MATα2[36]. When either major
isoform of MATβ interacts with MATα2 they increase the kcat  (turnover rate of an
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Figure 2
Figure 2  SAMe synthesis reaction. MAT enzyme catalyzes the biosynthesis of SAMe from the amino acid methionine and the energy molecule ATP. The sulphur
atom of methionine attacks the C5’ atom of ATP displacing the tripolyphosphate (PPPi) moiety to form SAMe. The PPPi is then hydrolyzed giving rise to
pyrophosphate (PPi) and orthophosphate (Pi).
enzyme-substrate  complex)  of  the  MATαβ  complexes[12,37,38]  and  increase  the
susceptibility to feedback inhibition by SAMe[37].
DYSREGULATION OF MATS IN LIVER DISEASE AND
CANCER
Many studies have demonstrated that MAT proteins play important roles in chronic
liver disease and hepatocarcinogenesis and a switch in their expression pattern is a
frequent event in liver cancers. MAT1A, which is mainly expressed in the liver and
maintains the differentiated state of hepatocytes, is downregulated in most cirrhotic
patients[39],  in patients with alcoholic hepatitis[40],  during de-differentiation and in
HCC[41,42]. Conversely, MAT2A and MAT2B, which are normally expressed only by
non-parenchymal cells of the liver and extrahepatic tissues, are induced in HCC[14,42,43].
This MAT1A to MAT2A/MAT2B switch contributes to reduced SAMe levels and is an
important determinant of liver injury, fibrosis and liver cancer development in both
rodents and humans[5].
MAT gene regulation and dysregulation in HCC
While MAT1A is a marker for normal differentiated liver, MAT2A and MAT2B are
markers  for  rapid  liver  growth  and  de-differentiation.  MAT2A  and  MAT2B  are
transcriptionally  induced  in  human  HCC,  during  rapid  liver  growth,  de-
differentiation, and in response to ethanol feeding in rodents[44-46]. Reduced hepatic
MAT activity has also been observed in cirrhotic patients, which explains why many
cirrhotic patients have hypermethioninemia[39]. In human HCC, the MAT1A:MAT2A
expression  ratio  has  been  inversely  correlated  with  cell  growth  and  genomic
instability and directly correlated with HCC apoptosis and overall DNA methylation;
a reduced ratio is a prognostic marker of more malignant and lower survival HCCs[47].
MATs are regulated at transcriptional, post-transcriptional and post-translational
levels by a complex network of mechanisms (Table 2). Many of these are dysregulated
in HCC and participate to alter MATs expression.
MAT1A transcriptional and epigenetic control
The  MAT1A  promoter  contains  binding  sites  for  multiple  transcription  factors,
including  hepatocyte  nuclear  factor  (HNF),  activator  protein  1  (AP-1),  CCAAT
enhancer binding protein (C/EBP),  c-MYC and glucocorticoids[48].  Some of  these
factors are determinants of liver-specific gene expression of MAT1A, such as HNF and
C/EBP, with the latter also control MAT1A expression by promoter regulation[48,49].
Prohibitin  1  (PHB1),  which  is  highly  expressed  in  normal  hepatocytes  and
downregulated in most HCCs, positively regulates MAT1A mRNA levels[50]. Finally, c-
MYC, MAFG and c-MAF, transcription factors that are overexpressed in human HCC
and CCA, have been shown to bind to a repressive E-box element in the human
MAT1A promoter to downregulate MAT1A transcription[8,9].
MAT1A  expression is  also regulated by DNA epigenetic  modifications.  Lower
MAT1A expression in HCC has been associated with promoter hypermethylation and
histone H4 deacetylation of its promoter[47,51]. Further investigation revealed a 750-base
pair (bp) region upstream of the MAT1A transcriptional start site for these epigenetic
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Table 2  Regulatory mechanisms of human MAT genes and proteins
MAT1A MAT2A MAT2B
Transcriptional regulation Glucocorticoids (+) CpG hypomethylation (+) AP-1 (+)
C/EBP (+) Histone H4 acetylation (+) NFκB (+)
CpG hypermethylation (-) c-MYB (+) SIRT1 (+)
Histone H4 deacetylation (-) SP-1 (+)
c-MYC (-) AP-1 (+)
MAFG (-) NFκB (+)
c-MAF (-) HIF1α (+)
PPARγ (-)
PPARβ (+)
HBx (+)
CREB (+)
Post-transcriptional regulation AUF1 (-) HuR (+) HuR (+)
miR-485-3p (-) Methylated-HuR (-) miR-21-3p (+)
miR-495 (-) miR-21-3p (+)
miR-664 (-) miR-34a (+)
miR-34b (+)
Post-translational regulation Phosphorylation (-) Phosphorylation (+) Phosphorylation (+)
Nitrosylation (-) Sumoylation (+) GIT1 interaction (+)
Oxidation (-) Acetylation (-) MATα2 interaction (+)
MATβ interaction (+)
(+): Positive regulation; (-): Negative regulation.
modifications[51]. In HepG2 cells and cirrhotic human livers, hypermethylation of sites
+10 and +88,  relative  to  the  transcriptional  start  site  have been reported to  also
downregulate  MAT1A  transcription[52].  Low  MAT1A  mRNA  levels  and  hyp-
ermethylation of both the MAT1A promoter and coding regions were also reported in
patients with advanced NAFLD[53].
MAT1A post-transcriptional control
Binding of AU-rich RNA binding factor (AUF1) to the 3’-untranslated region (UTR) of
MAT1A  mRNA negatively  regulates  its  stability.  There  is  an inverse  correlation
between AUF1 and Mat1a expression; de-differentiation of rat hepatocytes in culture
increases the expression of AUF1, contributing to the fall  in Mat1a  mRNA levels,
whereas  during  liver  development  AUF  expression  falls,  which  coincide  with
increased  Mat1a  expression;  AUF1  is  highly  expressed  in  human  HCC  and  its
knockdown increased MAT1A mRNA levels[54].
MAT1A mRNA is also regulated by microRNAs (miRNAs) in HCC[55,56]. Injection of
2-acetylaminofluorene in rats resulted in preneoplastic liver lesions, induction of both
miR-22 and miR-29b and inhibition of Mat1a mRNA expression[55]. MiR-485-3p, miR-
495,  and  miR-664,  which  are  increased  in  human  HCC  and  responsible  for  the
induction of LIN28B, an oncoprotein that is overexpressed in HCC and represses the
tumor suppressor Let-7,  have been shown to negatively regulate MAT1A.  These
specific miRNAs, through the downregulation of MAT1A,  lowered nuclear SAMe
levels,  leading to hypomethylation of the LIN28B  promoter region and increased
LIN28B expression[56]. Inhibition of these miRNAs reduced tumor growth in vitro and
in vivo by recovering MAT1A expression and inducing apoptosis[56].
MAT2A/MAT2B transcriptional and epigenetic control
MAT2A transcription is upregulated during liver growth and de-differentiation[57-59].
Like MAT1A, MAT2A is also regulated by multiple transcription factors including c-
MYB,  E2F  and  specificity  protein  1  (SP-1),  all  of  which  increase  its  promoter
activity[57,59]. The MAT2A promoter can also be induced by tumor necrosis factor-α
(TNF-α) via nuclear factor κβ (NF-κβ) and AP-1 elements in the promoter region[60].
Transforming growth factor β1 (TGF-β1) also increases the activity of the MAT2A
promoter  via  NF-κβ  in  hepatic  stellate  cells  (HSC)[61].  Multiple  PPAR  response
elements  (PPRE)  that  bind  nuclear  receptors  including  peroxisome-proliferator
activated receptors (PPAR) are present in the rat Mat2a promoter[62]. In normal liver
PPARγ is a marker of HSC quiescence, whilst PPARβ is induced in activated HSCs
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during liver fibrogenesis[63,64]. Both PPARγ and PPARβ occupy the same site on the
Mat2a  promoter  to  cause  opposite  effects[62].  PPARγ  negatively  regulate  Mat2a
transcription but during HSC activation PPARγ expression and activity fall, allowing
PPARβ to bind instead and induce Mat2a expression[62]. The MAT2A promoter is also
regulated by methylation and acetylation and in human HCC, MAT2A promoter is
hypomethylation and associate with higher histone H4 acetylation[58]. Expression of
MAT2A is also induced in a hypoxic tumor environment because hypoxia-inducible
factor-1α  (HIF-1α)  binds  to  a  consensus  sequence  within  the  MAT2A  promoter
activating its expression in human hepatoma cells[65]. Finally, hepatitis B X protein
(HBx) was shown to activate MAT2A gene transcription by facilitating NF-κB and
CREB  binding  to  the  MAT2A  promoter,  explaining  MAT2A  induction  in  HBV-
associated HCC[66].
Mechanism of MAT2B transcriptional regulation remains poorly characterized. In
the human liver cancer cell line HepG2, TNF-α can upregulate MAT2B-V1 mRNA but
not  MAT2B-V2  through an AP-1 and NF-κβ dependent  mechanisms[14].  Sirtuin 1
(SIRT1), a NAD+-dependent deacetylase, can also induce the expression of MAT2B[67].
MAT2B-V1 mRNA expression has also been found to be regulated by leptin in HepG2
cells by mechanisms that involve extracellular signal regulated kinase (ERK) and
AKT[68].
MAT2A/MAT2B post-transcriptional control
The stability of MAT2A mRNA can be influenced by the human RNA-binding (HuR)
protein and its methylated form, methyl-HuR[54]. The function of HuR depends on the
methylated state of the protein with methyl-HuR destabilizing target mRNAs and
HuR stabilizing them[54]. During hepatocyte de-differentiation as well as HCC, HuR is
induced but there is a decline in methyl-HuR, which results in a higher HuR/methyl-
HuR ratio.  For  MAT2A  this  causes  increased binding of  HuR to  MAT2A  mRNA
stabilizing it in HCC and de-differentiated hepatocytes[54]. HuR has also been shown
to stabilize MAT2B mRNA in a similar manner as MAT2A mRNA[67].
Drug-induced miRNAs including miR-21-3p have been shown to control MAT2A
and MAT2B  stability  in  HepG2 cells.  Either  treatment  with  the  anticancer  drug
berberine, which induces miR-21-3p, or overexpression of miR-21-3p itself causes
apoptosis and inhibition of growth by downregulating both MAT2A and MAT2B[69].
Most  recently  miR-34a and miR-34b,  tumor suppressor  miRNAs that  are  down-
regulated in multiple cancers including HCC, were shown to directly target MAT2A
mRNA and lower its expression[70].
The N6-methyladenosin (m6A) methyltransferase METTL16, has been shown to
methylate the 3’UTR of MAT2A  hairpins in HEK293T and HeLa cells[71,72].  In high
SAMe conditions methylation of  hairpin 1 (hp1)  of  the MAT2A  3’UTR promotes
intron  retention  and  nuclear  degradation  whilst  low  SAMe  levels  promote  the
enhanced binding of METTL16 to the hp1 of MAT2A  3’UTR leading to increased
splicing and MAT2A translation[71,72]. Regulation of MAT2A by METTL16 has not been
reported in HCC.
MAT proteins post-translational modifications
The  activity  and  stability  of  MAT  proteins  can  be  altered  by  post-translational
modifications including nitrosylation, phosphorylation and sumoylation. MATα1 has
cysteine at position 121 (C120 in human), which lies within the flexible gating loop,
can be both nitrosylated or  oxidized leading to  enzyme inactivation[73].  GSH, an
antioxidant,  and  other  thiol-reducing  agents  can  prevent  and  reverse  this
inactivation[74].  MATα2  cannot  be  inhibited  in  this  manner  as  glycine  is  at  this
position. Pho-sphorylation of MATα1 at threonine 342 (T341 in human) by protein
kinase C was reported 25 years ago, and this modification does not alter the kinetic
properties  of  this  enzyme[75].  However,  treatment  with  alkaline  phosphatase  to
dephosphorylate T342 lowered the activity of both MAT(α1)2 and MAT(α1)4in vitro[75].
Whether this is true in vivo has not been examined.
MATα2 and MATβ have also been reported to be phosphorylated. During liver
fibrosis and HSC activation, MATα2 and MATβ are phosphorylated via mitogen
activated protein kinase/ERK kinase (MEK) and ERK, respectively, which leads to
their  stabilization[76].  Analysis  revealed Y371/Y374 in MATα2 and T257/Y259 in
MATβ to be the sites of phosphorylation and importantly, mutation of these residues
inhibited HSC activation[76].  The use of in vitro  kinase assays, gene silencing, and
chemical  inhibitors  have  shown  that  MEK  could  be  responsible  for  the
phosphorylation of MATα2, whilst MATβ may be modified by ERK[76].
Sumoylation is a post-translational modification that involves the conjugation of
proteins with a small ubiquitin modifier (SUMO) that can lead to changes in the target
protein’s stability,  localization, tertiary interaction and activity[77].  Attachment of
SUMO-1 to a protein is achieved through the sole E2-conjugating enzyme, ubiquitin-
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conjugating enzyme 9 (UBC9)[78]. The addition of SUMO-1 to a protein is generally
associated with stability,  and it  has been shown that  MATα2 has three SUMO-1
modifications at the lysine residues K340, K369 and K394, that increase the stability of
MATα2  and  also  enhance  its  interaction  with  oncoproteins  such  as  B-Cell
CLL/lymphoma 2 (BCL-2)[77,79]. It has been shown that treatment with SAMe in liver
cancer cells reduces the expression and activity of UBC9[80].
While in normal liver MATα2 acetylation at K81 by the E1A binding protein (P300)
causes  its  ubiquitination  and degradation,  in  liver  disease  a  lack  of  acetylation
stabilizes the protein, and this has been associated with HCC development that is
attributed to the deacetylase HDAC3[81].
The effect of SAMe on MAT expression
While the expression of MATs can influence the steady-state levels of SAMe[36], SAMe
level can, in return, influence MAT expression. During de-differentiation of primary
hepatocytes in culture MAT1A expression falls while MAT2A expression is induced[82].
This effect is due to a fall in SAMe level since it can be blocked by the addition of
SAMe. Consistently, a fall in SAMe level (by restricting L-methionine in medium)
leads to rapid induction of MAT2A expression that is blocked upon the addition of
SAMe[58,83].  Treatment  with SAMe results  in  higher  methyl-HuR level  leading to
enhanced mRNA destabilization of MAT2A which may explain its negative effect on
MAT2A expression[54]. SAMe also inhibits MAT2B expression at baseline and prevents
leptin induced induction in hepatoma cells[68].
MAT proteins interactome
MAT proteins exhibit distinct interactomes in normal and diseased liver. All three
MATs interact with a variety of proteins regulating their expression and contributing
to liver injury and carcinogenesis.
MATα1 can act as a transcription co-factor by interacting with other E-box binding
regulatory proteins. MATα1 can heterodimerize with MAX in HCC to repress E-box-
driven promoter activity, which results in the negative regulation of the transcription
factors c-MYC, MAFG and c-MAF, and their oncogenic activity[9,50]. MATα1 has also
been found to interact with CYP2E1 to negatively regulate its protein expression by
inducing its proteasomal degradation[19]. Interestingly, MATα1 also interacts with p53
and DNA damage-regulated gene 1 (PDRG1) in hepatoma cells and in a mouse model
of  acute  liver  injury,  which  exhibited  reduced  total  MATα1  expression  but
accumulation of nuclear MATα1[84].  PDRG1  is an oncogene that is upregulated in
bladder, breast and colon cancer[85]. Interaction of PDGR1 with MATα1 in the nucleus
resulted in a decrease in MAT activity and DNA hypomethylation[84].  The role of
PDRG1 in HCC remains unknown.
MATα2 not only binds to and stabilizes BCL-2 protein, it  also enhances BCL-2
transcription in liver and colon cancer cell lines by binding to its promoter[79]. MATβ is
known to interact with HuR; when either of the MAT2B variants is overexpressed,
cytosolic HuR content increases leading to higher mRNA levels of HuR targets such
as cyclin D1 and cyclin A and proliferation[18]. MATβ also interacts with SIRT1, and
resveratrol increases this interaction by stabilizing them[67]. MATβ also interacts with
G-protein-coupled receptor kinase-interacting protein 1 (GIT1) to form a scaffold
complex that interacts and activates all components of the RAS/RAF/MEK/ERK
signaling pathway in  liver  cancer  cells,  promoting growth in  vitro  and in  vivo[7].
Interaction between MATβ and GIT1 appear to also stabilize MATβ[86]. Finally, both
MATα2 and MATβ are often overexpressed in parallel in multiple cancers and part of
the reason is that their interaction stabilizes both proteins[70].
CONSEQUENCES OF MAT GENES DYSREGULATION IN
THE DEVELOPMENT OF HCC
MAT genes deregulation has been widely associated with alterations that contribute
to liver disease and the development of HCC. MAT1A  downregulation increases
oxidative  stress,  progenitor  cells  expansion,  genomic  instability  and  other
mechanisms implicated in tumorigenesis,  whilst  MAT2A  and MAT2B,  which are
induced in HCC, confer growth and survival advantages to cancer cells (Reviewed in
Lu 2012)[5].  In  humans,  the  fall  in  MAT activity  observed in  cirrhotic  patients  is
thought to contribute to the pathogenesis and progression of the disease as well as
predisposition to HCC[39].
The Mat1a-KO mouse model
The Mat1a-KO mouse model has provided important insights into the mechanisms of
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how MAT1A might influence HCC development. This model is relevant to human
liver disease since MAT1A expression is markedly reduced in the majority of cirrhotic
patients[87]. Mice lacking Mat1a have markedly increased serum methionine levels and
chronically reduced hepatic SAMe (70% lower) and GSH (40% lower) levels. By three
months Mat1a-KO mice develop hepatic hyperplasia and are more susceptible to liver
steatosis in response to a choline-deficient diet. By eight months, Mat1a-KO mice
spontaneously develop NASH on a normal diet and by 18 to 20 months they develop
HCC[88]. The livers of Mat1a-deficient mice also exhibit oxidative stress caused by low
GSH levels, impaired mitochondrial function and increased expression of CYP2E1[34].
CYP2E1 is the principal P-450 enzyme responsible for the metabolism of hepatotoxins
such as alcohol, acetaminophen and CCl4  in the liver and has a critical role in the
generation of reactive oxygen species (ROS). Because of this, Mat1a-KO mice are more
susceptible to CCl4–induced liver injury[34].  Mitochondrial dysfunction is another
important  mechanism that  sensitizes  Mat1a-KO mice  to  liver  injury,  which  was
mainly  attributed  to  low levels  of  both  the  mitochondrial  chaperone  PHB1 and
oxidative  stress[34,89].  Our  recent  work  adds  loss  of  mitochondrial  MATα1,  an
important regulator of mitochondrial function, as another mechanism[19].
Genomic instability
Genomic  instability,  which arises  from the  large  number  of  genomic  mutations,
chromosomal aberrations, duplications, deletions and replication errors that cancer
cells carry, is a characteristic of most cancers including HCC and is considered an
early step in carcinogenesis[90,91]. Genomic instability may contribute to initiation of the
malignant transformation, progression of the cancer and even resistance to therapy,
influencing the overall prognosis of the cancer[92].
MAT1A regulates DNA methylation via SAMe and so MAT1A deficiency leads to
DNA hypomethylation, which may contribute to genomic instability. Interestingly,
alterations in the activity of MAT proteins and global DNA hypomethylation are
prognostic markers for human HCC possibly through genomic instability[93]. These
results  suggest  that  early  dysregulation  of  MAT  proteins  could  influence  the
progression  from  preneoplastic  lesions  to  cancer.  In  addition,  the  Apurinic
/Apyrimidinic  Endonuclease  1  (APEX1)  protein,  which  participates  in  the  base
excision repair of premutagenic apurinic/apyrimidinic (AP) sites, the most frequent
DNA lesion in cells, is markedly downregulated in Mat1a-KO livers. APEX1 protein
level is reduced in de-differentiated hepatocytes with reduced Mat1a expression and
low SAMe levels  and is  recovered by  SAMe treatment[94].  Taken together,  these
findings demonstrate that hepatic SAMe depletion promotes genomic instability by
different mechanisms contributing to malignant transformation.
Mitochondrial dysfunction
Along with oxidative stress,  mitochondrial  dysfunction represents  an important
trigger to hepatocarcinogenesis[95,96]. Although mitochondrial metabolism in malignant
cells is controversial, deregulated cellular energetics associated with mitochondrial
dysfunction are considered a common event in cancer[95]. As described above Mat1a-
KO livers exhibit mitochondrial dysfunction from multiple mechanisms, including
lower PHB1 expression, loss of mitochondrial MATα1 and increased expression of
CYP2E1.
Decreased PHB1 expression
A proteomics study identified several mitochondrial proteins to be downregulated in
Mat1a-KO mice from birth until the development of NASH[89]. PHB1 is a well-known
mitochondrial chaperone that stabilizes newly synthesized mitochondrial proteins
and maintains the organization and stability of mitochondrial nucleoids. PHB1 is
essential for mitochondrial function and was found significantly downregulated in
the livers of Mat1a-KO mice as compared to wild-type animals. In vitro experiment
suggested low SAMe level promoted increased PHB1 degradation, as SAMe addition
prevented the fall in PHB1 protein during culture[89]. However, a recent study showed
PHB1 and MAT1A exert reciprocal positive regulation on each other at the mRNA
level[50], adding another mechanism to low PHB1 expression in the Mat1a-KO liver.
The generation of a liver specific Phb1-KO mouse model confirmed that PHB1
hepatic deficiency predisposes to liver injury and malignant transformation. Liver-
specific Phb1-KO mice have liver injury at a very young age, abnormal mitochondria
and increased oxidative stress. Mice lacking Phb1 develop progressive fibrosis and
multi-focal HCC by 8-10 mo of age[97].  Although HCC could have developed as a
consequence  of  chronic  inflammation,  accumulating  evidence  support  a  tumor
suppressor function of PHB1 in the liver. For instance, PHB1 silencing in murine non-
transformed  AML12  cells  increased  cyclin  D1,  H19,  and  IGF2  expression  and
enhanced E2F binding to  the cyclin  D1 promoter  and proliferation[97].  PHB1 can
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cooperate with CCCTC-binding transcription factor (CTCF) to negatively regulate
H19 and IGF2 expression,  both of  which are  induced in HCC[98].  Reduced PHB1
expression has also been shown to induce IL-8 transcription by activating NF-κB and
AP-1, resulting in enhanced IL-8 expression and release to promote tumorigenesis[99].
Finally,  PHB1  also  acts  as  a  negative  regulator  of  WNT  signaling,  and  its
downregulation causes the induction of multiple WNT ligands and downstream
activation of canonical WNT β-catenin signaling in murine liver and human HCC
cells, in part through E2F[100].
It should be noted that the tumor suppressor role of PHB1 is highly controversial
since  PHB1  expression  is  increased  in  other  cancers.  PHB1  is  also  found in  the
nucleus, where it has been shown to interact with Rb and p53 among other proteins to
bring  about  a  change  in  transcriptional  activities  of  E2F  and  p53[101].  Different
subcellular  localizations  and  post-translation  modifications  may  explain  the
contradictory tumor regulatory activities of PHB1 in different cell types.
Mitochondrial MATα1
Recently  MATα1  was  shown  to  be  present  in  the  mitochondrial  matrix  in
hepatocytes[19].  Mat1a-KO  hepatocytes  had  reduced  mitochondrial  membrane
potential  and higher  mitochondrial  ROS,  both  of  which  were  normalized  when
MAT1A was overexpressed. Oxygen consumption rate, ATP production and maximal
and spare respiratory capacities were all reduced in Mat1a-deficient mitochondria,
supporting the negative effect that MAT1A deficiency has on mitochondrial function.
Another important finding that may contribute to mitochondrial dysfunction and
liver  injury  in  Mat1a-KO  mice  is  the  interaction  of  MATα1  and  CYP2E1  in  the
mitochondria.  Mat1a  deficiency  leads  to  higher  CYP2E1  mitochondrial  levels.
Mitochondrial  CYP2E1  also  regulates  the  production  of  ROS  and  is  known  to
contribute to liver injury and mitochondrial dysfunction[102,103].  MATα1 negatively
regulates CYP2E1 expression at mRNA and protein levels, with the latter being the
dominant  mechanism that  involves  methylation of  CYP2E1 R379,  promoting its
proteasomal degradation[19].
MATα1 was found to also interact with important mitochondrial proteins including
several subunits of the electron transport chain complexes, which raises the possibility
that MATα1 could be regulating mitochondrial function in multiple ways. These
findings highlight a critical role of MATα1 in regulating mitochondrial function and
could provide  a  novel  target  for  the  treatment  of  different  liver  diseases  where
mitochondrial dysfunction plays a key role. Taken together, reduced mitochondrial
MATα1 could play a key role in the mitochondrial dysfunction that is often observed
in HCC[104].
Cancer stem cells
Cancer stem cells, also known as tumorinitiating cells, are known to play a central role
in tumor development, metastasis and recurrence and are considered key therapeutic
target for cancer treatment. Hepatic oval cells are the cancer stem cells of the liver and
important contributors of hepatocarcinogenesis[105]. They are quiescent in normal adult
liver and low in number and expand during severe and prolonged injury as seen in
various models of experimental carcinogenesis[106].
Methyl-deficient diets have been used to induce oval cell proliferation and HCC
formation in susceptible models such as p53−/−  mice[107].  Mat1a-KO livers contain
increased populations of liver cancer stem cells (or CD133+/CD49f+ oval cells), as they
age[108].  These  cells  have  increased  expression  of  several  oncogenes  and  are
tumorigenic  in  vivo.  Interestingly,  Mat1a-KO’s  cancer  stem cells  show increased
MAPK signaling with enhanced ERK activity,  like  Mat1a-KO’s  hepatocytes,  and
increased oncogenic signaling (K-Ras and Survivin)[108]. Constitutive ERK activation
makes these cells resistant to the apoptotic effect of TGF-β, a well-known growth
inhibitor in hepatocytes[109,110]. How SAMe deficiency allows expansion of oval cells
remains unknown.
Dysregulated pathways
Increasing evidence indicates that the deregulation of various signaling pathways
progressively increase with HCC progression and has a prognostic value. The MAT1A
to MAT2A/MAT2B  switch is also associated with activation of multiple signaling
pathways including RAS/ERK[76,86,111], IκB kinase (IKK)/NF-kB[14,60], Phosphoinositide
3-kinase (PI3K)/AKT[68,112,113] and Liver kinase B1 (LKB1)/AMPK-activated protein
kinase (AMPK)[114]. Increased sumoylation[80] and c-MYC expression[8], which are well-
known contributors of hepatocarcinogenesis, have also been associated with reduced
hepatic SAMe levels.
ERK signaling
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ERK signaling is tightly regulated in normal cells but uncontrollably active in cancer
cells,  being  one  of  the  several  growth signals  associated  with  highly  malignant
HCCs[115,116].  ERK activity is regulated by the dual-specificity MAPK phosphatase
(DUSP1). DUSP1 is a member of a family of dual-specificity MAPK phosphatases that
dephosphorylates both serine/threonine and tyrosine residues[117]. Interestingly, there
is a reciprocal regulation between DUSP1 and ERK[111]. Transient activation of ERK
leads  to  catalytic  activation  DUSP1,  which  in  turn  inhibits  ERK  activity  by
dephosphorylation[118]. DUSP1 feedback inhibits ERK and this activity of DUSP1 is
crucial for the regulation of ERK activity in liver cells.  However, prolonged ERK
activation induces the phosphorylation of DUSP1 at the Ser296 residue rendering the
DUSP1 protein susceptible to proteasomal degradation[119]. In human HCC, DUSP1
expression is negatively correlated with proliferation and microvessel density and
positively with survival[118].
Hepatic DUSP1 expression is decreased in Mat1a-KO mice both at the mRNA and
protein levels, being more pronounced at the protein level and was normalized after
SAMe treatment[111]. SAMe increased DUSP1 mRNA level by enhancing p53 binding
to its consensus element in the DUSP1 promoter, which is known to activate DUSP1
transcriptionally[111]. Increased binding of p53 to the DUSP1 promoter in SAMe fed
mice  was  due  to  the  fact  that  SAMe stabilizes  APEX1,  which  is  a  known trans-
activator of p53[94]. DUSP1 lower protein level was attributed to its faster degradation
due to increased proteasomal activity in Mat1a-KO mice. SAMe treatment normalized
proteasomal activity, increasing DUSP1 protein level and normalized ERK activity in
Mat1a-KO mice[111]. These findings suggest that SAMe deficiency leads to uncontrolled
ERK activation due at  least  in part  to decreased DUSP1 expression during HCC
development.  ERK signaling was also found to be regulated by MAT2B  since its
knockdown inhibited the activation of MAPK/ERK pathway induced by leptin in
liver  cancer  cell  lines[68].  Finally,  as  mentioned earlier,  the  MATβ-GIT1 complex
efficiently binds to MEK and ERK leading to their activation. Consistent with this,
overexpression of MAT2B or GIT1 in the HCC cell line Huh7 enhanced tumor growth
and metastasis in a mouse orthotopic HCC model[86].
LKB1-AMPK signaling
Even though LKB1 is considered a tumor suppressor in a variety of cancers[120], its role
in liver carcinogenesis remains controversial given the fact that both reduced and
increased  LKB1  levels  have  been  reported  in  human  HCC  correlating  with
prognosis[121-124]. In recent years, several publications have supported the oncogenic
role of LKB1 in liver cancer[122-125].
LKB1 phosphorylates and activates AMPK, a central metabolic sensor, to control
cell growth in response to environmental nutrient changes. Indeed, the LKB1/AMPK
signaling  pathway  has  tumor  suppressor  activity  since  it  serves  as  a  metabolic
checkpoint  arresting  cell  growth  in  conditions  of  nutrient  deprivation  or  low
intracellular ATP levels[126]. In the liver the activation of LKB1 and AMPK leads to the
production of nitric oxide (NO) and is required for hepatocyte proliferation, as seen in
regenerating livers after partial hepatectomy and hepatocyte growth factor (HGF)
treated rat hepatocytes[114]. Interestingly, early during liver regeneration hepatic SAMe
level falls and exogenous SAMe inhibits regeneration[127]. The thought is that SAMe
level  needs  to  fall  in  order  to  release  the  inhibitory  tone  it  exerts  on  mitogenic
pathways. Although Mat1a–KO mice have higher basal proliferation, they exhibit
impaired liver regeneration because hepatic SAMe level remained unchanged[127].
Consistent  with  this,  in  the  presence  of  SAMe,  protein  phosphatase  2A (PP2A)
interacts  with  AMPK,  leading  to  its  dephosphorylation  and  inactivation.  One
explanation for the fall in hepatic SAMe level early in liver regeneration is due to
increased NO formation, which can inactivate MATα1[128,129].
Activation of the LKB1/AMPK pathway may contribute to hepatocarcinogenesis
through other mechanisms as well. Increased LKB1 and AMPK activity results in
nuclear to cytoplasmic HuR translocation and the subsequent stabilization of several
cyclin  mRNAs  enhancing  cell  proliferation[130].  LKB1/AMPK  activation  is  also
required for survival of HCC cells derived from Mat1a-KO livers, named SAMe-D[114].
LKB1 can regulate AKT-mediated cell survival independent of PI3K, AMPK, and
mTOR2 (mammalian target of rapamycin complex). LKB1 is hyperactivated in SAMe-
D  cells  and  can  control  survival  through  the  phosphorylation  and  cytoplasmic
retention of p53. In normal cells, p53 expression is maintained at a low level and is
inactivated by Mdm2-mediated nuclear to cytosol transportation and proteasomal
degradation. In response to oncogenic insults, p53 translocates to the nucleus to exert
its tumor suppressor activity and activate pathways associated with DNA repair, cell
cycle arrest and apoptosis. Notably, HuR nucleocytoplasmic shuttling also stabilizes
p53  mRNA. Supporting these findings, increased cytoplasmic staining of p53 and
phospho-LKB1 were found in the Mat1a-KO livers and in livers from human HCC
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derived from both NASH and alcoholic steatohepatitis[131]. Figure 3 summarizes the
mechanisms of HCC development in the Mat1a-KO mouse model.
MAT DYSREGULATION IN CCA
CCA is, after HCC, the second most common primary hepatic malignancy and like
HCC, its development involves MAT genes deregulation. MAT1A is highly expressed
also in normal bile duct epithelial cells and is repressed during chronic cholestasis and
in  murine  and  human  CCA[8].  There  are  common  mechanisms  of  MAT  genes
deregulation between HCC and CCA. For example, hypermethylation of the MAT1A
promoter has also been observed in CCA. The transcription factors c-MYC, MAFG
and c-MAF, which are all induced both in HCC and CCA, also negatively regulate
MAT1A transcription in CCA by binding to its repressor E-box promoter region[8].
PHB1,  which  is  also  downregulated  in  most  human CCAs,  positively  regulates
MAT1A  while  suppressing  c-MYC,  MAFG,  and  c-MAF  expression  in  mice[9,50].
Consistently,  reduced  PHB1  expression  predisposes  to  the  development  of
cholestasis-induced CCA[8,50]. Figure 4 summarizes changes in MATs and SAMe in
HCC and CCA as compared to normal liver.
TARGETING MATS IN LIVER CANCER
Restoration of SAMe levels
The Mat1a-KO mouse model demonstrates that the switch from Mat1a to Mat2a leads
to hepatic SAMe deficiency and hypermethioninemia[88]. Patients with human liver
cirrhosis[39], alcoholic hepatitis[40], advanced NAFLD[53], as well as HCC [42]  all have
lower MAT1A mRNA level. The restoration of hepatic SAMe level appears to be an
obvious therapy to overcome the fall  in SAMe level due to the MAT1A/MAT2A
switch. There have been very few human trials that examined SAMe in chronic liver
disease. One study showed that SAMe treatment (1,200 mg orally per day in three
divided doses) for two years improved the survival or delayed liver transplantation in
patients who had alcoholic liver cirrhosis with less advanced liver disease (Child’s
class  A  and  B)[132].  However,  this  was  a  post-hoc  analysis,  so  it  remains  to  be
confirmed. Another study in patients with hepatitis B-related advanced-stage (stages
B-C) HCC who received 1000 mg of SAMe two hours before surgery intravenously
and continued for five consecutive postoperative days showed a reduction of alanine
aminotransferase and aspartate transaminase levels, delayed recurrence and a greater
24-mo survival rate as well as a lower risk of complications[133]. However, analysis by
the Cochrane Hepato-Biliary group using a total of 330 alcoholic liver disease patients
treated with SAMe in 8 clinical trials did not confirm the beneficial effects of SAMe in
human liver cirrhosis although they were small with variable quality, which resulted
in the meta-analysis failing to show a significant benefit of SAMe treatment[134]. At the
present time the verdict on the effectiveness of SAMe in chronic liver disease is still
out and its utility in chemoprevention of HCC remains to be studied.
In CCl4-induced liver injury SAMe treatment prevented the activation of HSCs by
inhibiting  the  collagen  promoter  as  well  as  downregulating  TGF-β-induced
extracellular matrix protein,  α-smooth muscle actin (α-SMA)[135].  It  has also been
demonstrated that SAMe is selectively pro-apoptotic in liver cancer cells but anti-
apoptotic  in  normal  hepatocytes[136,137].  This  property  makes  SAMe  particularly
attractive as a chemopreventive agent. Indeed, SAMe can chemoprevent against HCC
in several preclinical models[5]. However, SAMe was ineffective at treating established
tumors in an orthotopic HCC model[138]. Investigation into this revealed that buildup
of SAMe in the liver was prevented by the compensatory induction of glycine-N
methyl transferase (GNMT), an important enzyme abundantly expressed in the liver
that is responsible for catabolizing SAMe and keeping SAMe level within a tight
range[5,138]. Although acute pharmacologic SAMe treatment can transiently increase
liver SAMe level by 10-fold, prolong SAMe treatment induced GNMT expression so
that SAMe level increased only 30%, which is insufficient to exert a pro-apoptotic
effect [138].  However,  in  human  cirrhosis  and  HCC  GNMT  express  is  often
downregulated[139], so the efficacy of SAMe for HCC treatment in human warrants
further investigation. At present, there are two SAMe ongoing clinical trials in HCC
treatment. One (NCT03178929) is designed to investigate SAMe treatment (2000 mg,
P.O.) in HCC patients (Barcelona Clinic Liver Cancer 0/A) after radical treatment,
where tumor recurrence is the endpoint. The other (NCT02586285) aims to study the
SAMe treatment (500-1000 mg, iv, per day) in HCC patients after curative treatment.
Although targeting SAMe has been the central focus for treatment, therapies that
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Figure 3
Figure 3  Mechanisms of hepatocellular carcinoma development in the Mat1a knockout mouse. Multiple mechanisms are known to influence hepatocellular
carcinoma development in the Mat1a-KO mouse. These include: oxidative stress due to lower GSH levels and higher CYP2E1 expression; mitochondrial dysfunction
due to reduced PHB1 and increased mitochondrial CYP2E1 levels; increased sumoylation, stabilizing MATα2, which acts as a transcription factor to enhance BCL-2
transcription as well as directly interacting with BCL-2 leading to its stabilization; enhanced activation of the LKB1/AMPK pathway which leads to the cytoplasmic
translocation of HuR from nucleus and subsequent stabilization of cyclins; aberrant activation of ERK which promotes uncontrolled cell growth; enhanced genomic
instability due to DNA hypomethylation and impaired DNA repair machinery and increased number of liver cancer stem cells with tumorigenic potential.
target the MAT proteins themselves could also offer potential benefit to which some
of these are described below.
Restoring the expression of endogenous MAT1A
Overexpressing MAT1A in the liver cancer cell line Huh7 resulted in a stable increase
in  SAMe  levels,  an  induction  in  tumor  suppressor  genes,  downregulation  of
angiogenesis  genes,  reduced cell  growth and increased apoptosis  in  vitro  and in
vivo[140].  This is a proof of principle that raising MAT1A expression in liver cancer
could be an effective treatment strategy. While delivering MAT1A gene therapy to
HCC cells is not a suitable approach, targeting miRNAs that downregulate MAT1A
expression might be feasible. MiR-485-3p, miR-495, and miR-664 are three miRNAs
that  are  increased  in  human  HCC  that  directly  target  MAT1A  at  the  3’UTR[56].
Treatment  with  siRNA  against  any  of  the  miRNAs  resulted  in  higher  MAT1A
expression, reduced HCC growth in an orthotopic HCC model[56]. Higher SAMe level
as  a  result  can also downregulate  MAT2A/MAT2B to slow HCC growth.  Taken
together, raising endogenous MAT1A expression and hence SAMe level in the HCC
cells is an attractive treatment approach that deserves further study.
Targeting of MAT proteins
Therapeutic agents to target MATα2 have been proposed for many years. In the 1970s
methionine analogs were suggested to act as substrate-competitive inhibitors and
proposed as chemotherapeutic agents[141]. Stilbene derivatives (FIDAS agents) have
been  proposed  as  inhibitors  of  MATα2,  but  these  compounds  are  unlikely  to
specifically inhibit MATα2 because of their ability to bind multiple proteins targets[142].
Using molecules that directly target the active site of MATα2 may be problematic as
this protein is expressed in most extrahepatic cells which require MATα2 as the SAMe
generator. In addition, the high level of sequence and structural identity between
MATα1 and MATα2 makes it difficult to design active site molecules that would only
target one these proteins. One strategy is to target the interaction of the MATα2β
complexes as these complexes provide a proliferative advantage to HCC cells by
lowering steady state SAMe level, stabilizing each other as well as activating several
mitogenic pathways[7,43,68,86]. A novel allosteric inhibitor has been shown to bind to the
interacting site of these proteins, which demonstrated promise in lung cancer cells[13].
It remains to be examined in liver cancer models.
Targeting a posttranslational modification could also be a good strategy to only
target MAT proteins that are contributing to the pathogenesis of HCC. Designing a
molecule for a specific modification on MATα1, MATα2, or MATβ may be possible to
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Figure 4
Figure 4  MAT genes expression pattern in normal liver and liver cancer.MAT1A is mainly expressed in normal
liver by hepatocytes and bile duct epithelial cells; whereas MAT2A and MAT2B are expressed in extrahepatic tissues
and by the non-parenchymal cells in the liver. During liver disease and malignant transformation there is a switch
from MAT1A to MAT2A/MAT2B, being MAT2A and MAT2B the predominant MAT genes expressed in HCC and CCA.
MAT1A maintains the differentiated state of the liver whilst MAT2A and MAT2B give proliferative and survival
advantages to cancer cells. SAMe positively regulates MAT1A and negatively regulates MAT2A and MAT2B as well
as feedback inhibits MATII. Accordingly, steady state SAMe levels are lower in patients with chronic liver disease and
liver cancer due to the switch from MAT1A to MAT2A/MAT2B.
stabilizes MATα1 whilst destabilizing MATα2 and MATβ. For instance, sumoylation
on MATα2 facilitated BCL-2 induction in HCC, and induced chemoresistance in HCC
cells[79]. Using small molecules to block the addition of SUMO to MATα2 would lower
its  expression  as  well  as  that  of  BCL-2.  Similarly,  MATα2  and  MATβ  are  both
stabilized by phosphorylation at specific residues which facilitated HSC activation[76].
HSC activation is an important mediator of liver fibrosis, and therefore blocking the
site-specific phosphorylation of these MAT proteins could be a novel treatment for
liver  fibrosis.  As  mentioned before,  MATβ has  been  implicated  to  promote  cell
survival in HCC due to its interaction with the MEK/ERK/MAPK pathway[68,86]. The
discovery that MATβ interacted with GIT1 and caused the amplification of RAS-
mediated MAPK activation provides another novel target where a molecule could
block  this  protein-protein  interaction  to  inhibit  MAPK  signaling  and  cell
proliferation[7].
MATs as potential molecular markers in liver cancers
Epigenetic  alterations  including  DNA  methylation  are  recognized  as  a  major
characteristic in HCC and may serve as diagnostic and prognostic biomarkers[143].
MATα1 to MATα2 switch and low SAMe level are associated with HCC development
and strongly predict patients’ survival[47,144]. High MAT1A expression in human HCC
is negatively correlated to tumor size (> 5 cm), whilst up-regulation of MAT2A  is
positively correlated to serum alpha-fetoprotein level and one-year recurrence after
hepatectomy[145]. Moreover, the MATα1 to MATα2 switch may promote HCC invasion
and metastasis and lower patient recurrence-free survival[146]. All these suggest MATs
may serve as diagnostic and prognostic molecular markers in HCC and likely CCA as
well.
CONCLUSION
Taken together, accumulating evidence demonstrates the importance of MAT genes in
liver tumorigenesis. Part of the mechanism is related to a lowering in the steady state
SAMe level. However, all three MATs are found in the nucleus where they regulate
gene expression via epigenetics as well as bona fide transcription factor and cofactors.
They also have distinct interactomes and affect a myriad of signaling pathways. SAMe
is an attractive chemopreventive and possibly therapeutic agent in liver cancer and its
efficacy  in  both  warrant  investigation.  Small  molecules  that  inhibit  interactions
between MATβ-GIT1 or MATα2-β, both of which provide proliferative advantages to
liver cancer cells,  and targeting posttranslational modifications that can increase
MAT1A and/or lower MAT2A/2B are all exciting future directions for translating the
knowledge  gained  from  understanding  mechanisms  of  MAT  dysregulations  to
therapy in liver cancer.
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